4,658 Shares in United Therapeutics Corporation $UTHR Bought by Engineers Gate Manager LP

Engineers Gate Manager LP bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,658 shares of the biotechnology company’s stock, valued at approximately $2,524,000.

Other large investors have also added to or reduced their stakes in the company. California State Teachers Retirement System lifted its holdings in shares of United Therapeutics by 55,526.2% in the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after acquiring an additional 33,229,108 shares during the last quarter. BlackRock Inc. bought a new position in shares of United Therapeutics during the 2nd quarter valued at $2,868,735,000. Jupiter Topco LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at $450,140,000. Norges Bank purchased a new position in United Therapeutics in the 4th quarter worth $293,418,000. Finally, Bank of New York Mellon Corp purchased a new position in United Therapeutics in the 2nd quarter worth $159,522,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 1.1%

UTHR stock opened at $502.70 on Tuesday. The firm’s 50-day moving average price is $520.02 and its two-hundred day moving average price is $540.96. United Therapeutics Corporation has a 12-month low of $396.12 and a 12-month high of $609.35. The stock has a market capitalization of $21.56 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 2.49 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $6.41 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,195,871.40. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $552.40, for a total value of $5,247,800.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,379,381.20. This trade represents a 19.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 364,575 shares of company stock worth $191,659,133. 8.60% of the stock is owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.